title: Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies.
abstract: The family of epidermal growth factor receptors (EGFRs) is overexpressed in many gynecologic malignancies. Extensive preclinical studies of these receptors demonstrate that they play an important role in supporting the growth of a wide variety of malignancies and that interruption of receptor function or signaling from these receptors leads to inhibition of tumor growth or in certain cases tumor regression. Recently, many therapeutic agents targeting this receptor have entered the clinic and phase II clinical studies have demonstrated activity in lung cancer, colon cancer, and head and neck malignancies. Phase II trials of both small molecule inhibitors of EGFR and antibody-based inhibitors are underway in both cervical and ovarian cancer and emerging data suggests that their activity in unselected women with advanced gynecologic malignancies is very modest. Recently, molecular analysis of lung cancers has identified that the response to small molecule inhibitors of EGFR is highly correlated with activating mutations within the EGFR. It is possible that these agents will be highly effective in a small subset of patients with gynecologic malignancies whose tumors are dependent on EGFR signaling, perhaps through an activating mutation in EGFR or its downstream pathway. Until additional research can identify the subset of patients most likely to benefit from this targeted therapy, treatment for women with gynecologic malignancies with EGFR inhibitors should be limited to investigational trials. It is critical that these trials have access to tissue of responding and nonresponding patients so to determine the rational use of these agents in the treatment of gynecologic malignancies.
authors.affiliation: Department of Oncology, Massachusetts General Hospital, Cox 6, 100 Blossom St., Boston, MA, 02114, USA.
authors.forename: Ami P
authors.initials: AP
authors.lastname: Vaidya
authors.forename: Aric D
authors.initials: AD
authors.lastname: Parnes
authors.forename: Michael V
authors.initials: MV
authors.lastname: Seiden
mesh_terms: D001682:Biological Availability; D017322:Clinical Trials, Phase II as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D016889:Endometrial Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000627:therapeutic use*; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D006801:Humans; D020714:Maximum Tolerated Dose; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology
chemical_list: D066246:ErbB Receptors
references.citation: J Clin Oncol. 2002 May 1;20(9):2240-50
references.pmid: 11980995
references.citation: J Clin Oncol. 2004 Aug 1;22(15):3003-15
references.pmid: 15210739
references.citation: Oncology (Williston Park). 2003 Nov;17(11 Suppl 12):23-8
references.pmid: 14682120
references.citation: Crit Rev Oncol Hematol. 2001 Apr;38(1):17-23
references.pmid: 11255078
references.citation: J Clin Oncol. 2002 Nov 1;20(21):4292-302
references.pmid: 12409327
references.citation: Cancer Res. 2001 Mar 1;61(5):2169-76
references.pmid: 11280782
references.citation: Ai Zheng. 2004 May;23(5):568-72
references.pmid: 15142456
references.citation: Br J Cancer. 2006 Jan 16;94(1):85-92
references.pmid: 16306877
references.citation: J Clin Oncol. 2001 Jul 1;19(13):3267-79
references.pmid: 11432895
references.citation: Clin Cancer Res. 1999 Mar;5(3):577-86
references.pmid: 10100709
references.citation: Ann Oncol. 2003 Jun;14(6):922-30
references.pmid: 12796031
references.citation: Cancer Res. 1995 Dec 1;55(23):5536-9
references.pmid: 7585629
references.citation: J Clin Oncol. 2003 Jan 15;21(2):283-90
references.pmid: 12525520
references.citation: Science. 2004 Jun 4;304(5676):1497-500
references.pmid: 15118125
references.citation: Tumour Biol. 1998;19(5):364-73
references.pmid: 9701727
references.citation: Clin Pharmacokinet. 2001;40(4):297-306
references.pmid: 11368294
references.citation: N Engl J Med. 2004 May 20;350(21):2129-39
references.pmid: 15118073
references.citation: Int J Gynecol Cancer. 2001 Mar-Apr;11(2):119-29
references.pmid: 11328410
references.citation: J Natl Cancer Inst. 2001 Sep 19;93(18):1375-84
references.pmid: 11562388
references.citation: Br J Cancer. 1995 Apr;71(4):758-62
references.pmid: 7710941
references.citation: J Clin Oncol. 2004 Jan 1;22(1):175-84
references.pmid: 14701780
references.citation: Gynecol Oncol. 1999 Apr;73(1):62-71
references.pmid: 10094882
references.citation: Int J Biochem Cell Biol. 1999 Jun;31(6):637-43
references.pmid: 10404636
references.citation: Cancer Treat Rev. 2004 May;30(3):255-68
references.pmid: 15059649
references.citation: Cancer. 2001 Dec 15;92(12):3068-75
references.pmid: 11753986
references.citation: Br J Cancer. 2004 Feb 9;90(3):566-72
references.pmid: 14760365
references.citation: J Biol Chem. 1999 Jun 18;274(25):17612-8
references.pmid: 10364198
references.citation: J Clin Oncol. 2002 Sep 15;20(18):3815-25
references.pmid: 12228201
references.citation: Clin Cancer Res. 1999 Oct;5(10):2877-83
references.pmid: 10537356
references.citation: J Pharmacol Exp Ther. 1999 Nov;291(2):739-48
references.pmid: 10525095